Compare Cytokinetics Inc (CYTK) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs M&T Bank Corporation — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while M&T Bank Corporation trades at $251.93 (market cap $36.27B). The key difference: M&T Bank Corporation is far larger — about 3.4× Cytokinetics Inc's market cap, and M&T Bank Corporation pays a 2.39% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MTB | |
|---|---|---|
Market Cap | $10.78B | $36.27B |
Sector | Technology | Financials |
52-Week High | $87.26 | $254.04 |
52-Week Low | $33.23 | $178.63 |
Enterprise Value | $10.88B | — |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
M&T Bank Corporation (MTB) trades at $250.45, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock is supported by strong fundamentals, including a net income margin of 30.85% and a P/E ratio of 13.26, indicating reasonable valuation. Recent Q2 2026 results showed record EPS of $5.35, exceeding expectations, driven by loan growth and net interest income. The consensus price target is $255.92, suggesting modest upside from current levels.
The outlook for MTB remains positive, supported by operational excellence and dividend payments, but risks include macroeconomic sensitivity and competitive pressures in regional banking. Investor sentiment is cautiously optimistic, with analysts largely holding a neutral to buy stance, while institutional ownership trends and cash flow management will be key to sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
